Exome Asset Management’s Biohaven BHVN Stock Holding History

Exome Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-39,900	Closed	-$959K	–	70
2025 Q1	$959K	Buy	39,900 +11,741	+42%	+$414K	0.85%	41
2024 Q4	$1.05M	Buy	+28,159	New	+$1.31M	0.79%	44
2024 Q3	–	Sell	-57,800	Closed	-$2.01M	–	65
2024 Q2	$2.01M	Buy	+57,800	New	+$2.29M	1.79%	27
2024 Q1	–	Sell	-45,467	Closed	-$1.95M	–	55
2023 Q4	$1.95M	Buy	+45,467	New	+$1.41M	1.92%	22

Other funds holding BHVN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Exome Asset Management's BHVN Position: Q2 2025 in Review

Exome Asset Management sold out of Biohaven (BHVN) in Q2 2025, closing a stake of 39,900 shares — an estimated $959K sold.

Exome Asset Management first reported a position in BHVN in Q4 2023 and held it in 4 quarters. The position peaked at $2.01M in Q2 2024. 249 funds tracked by Wall St. Rank hold BHVN as of Q2 2025.

Exome Asset Management reported no remaining Biohaven position as of Q2 2025 after selling out during the quarter.
Exome Asset Management sold 39,900 Biohaven shares in Q2 2025, an estimated $959K.
Exome Asset Management first reported a position in Biohaven in Q4 2023 and held it in 4 quarters.
Exome Asset Management's Biohaven position peaked at $2.01M in Q2 2024.
249 funds tracked by Wall St. Rank held Biohaven as of Q2 2025.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.